News

News
Share this article
25 February 2021

March webinar: High Content Screening at the European Lead Factory

Phenotypic screening is a powerful approach to identifying novel chemical starting points for drug discovery. It uses cell-based assays and advanced data analytics to develop quantitative fingerprints that can uncover new drug targets and pathways underpinning disease-related biology.

News
Share this article
10 February 2021

ELF webinar: Guidelines for High Throughput Screening assay development

How to optimise your assay for High Throughput Screening (HTS) at the European Lead Factory (ELF). This was the topic of the latest ELF webinar, which took place on Thursday 28 January.

News
Share this article
28 January 2021

New study elucidates role of tryptophan-metabolizing enzymes in cancer immunotherapy

In a new article, published in Frontiers in Immunology, researchers from the Netherlands Translational Research Center B.V. (NTRC), explain the role of the enzyme IDO1 in models of cancer immunotherapy.

News
Share this article
11 January 2021

ELF project member spotlight: James Duffy, MMV

Dr James Duffy is a Director of Drug Discovery at the Medicines for Malaria Venture (MMV), a not-for-profit product development partnership (PDP) working to reduce the burden of malaria by discovering, developing and delivering new, effective and affordable antimalarial drugs. MMV has been partnering with the European Lead Factory (ELF) since 2018 to run high-throughput screens for novel antimalarials. We spoke with James about his experience of working with ELF, the importance of investing in early drug discovery, and the progress made to date with the MMV-ELF screening programmes.

News
Share this article
08 January 2021

How ELF can boost SME drug discovery programmes: examples from the chronic pain disease area

The focus of the second European Lead Factory (ELF) webinar, which took place on Thursday 10 December, was on small and medium-sized enterprises (SMEs) and how ELF can help SMEs achieve their drug discovery ambitions.

News
Share this article
17 December 2020

European Lead Factory launches multiple approaches aiming to discover novel SARS-CoV-2 antiviral molecules

The European Lead Factory (ELF) offers a pharmacological strategy to aid in the discovery of new candidate molecules against SARS-CoV-2 causing COVID-19. The strategy is tailored to the needs of academic teams or SMEs in Europe and removes two important roadblocks: access to unique, novel, drug-like chemical starting points and the search for a feasible economic model to develop antiviral molecules.

News
Share this article
16 December 2020

European Lead Factory webinar: How to optimise your assay for High Throughput Screening

Have you identified a disease mechanism that should be explored in a drug discovery project? Then you may have also considered developing a screening assay to find new chemical starting points that could serve as candidates for drug development.

News
Share this article
27 November 2020

European Lead Factory webinar on 10 December: How ELF can boost SME drug discovery programmes

Registration is now open for the second in a series of webinars hosted by the European Lead Factory (ELF).

News
Share this article
25 November 2020

Embracing the new normal: The European Lead Factory kicks off monthly webinar series

On Thursday 12 November, the European Lead Factory (ELF) hosted the first in a series of webinars. With these webinars, the ELF team aims to engage and maintain contact with the broader scientific community, now that live conferences and in-person meetings are not possible. The team also hopes to lower the barrier for researchers who may be interested in collaborating with ELF to further their drug discovery ambitions.

News
Share this article
04 November 2020

ELF project member spotlight: Jason Swedlow, University of Dundee

Phenotypic screening is a powerful approach to identifying novel chemical starting points for drug discovery, offering the potential to uncover new drug targets and pathways underpinning disease-related biology. High Content Screening (HCS) is one of the phenotypic screening approaches offered by the European Lead Factory (ELF). To find out more about HCS and all it entails, we spoke to Professor Jason Swedlow, head of the National Phenotypic Screening Centre (NPSC) at the University of Dundee – one of ELF’s academic partners.

Pages